-
Chairs:
W.-A. Hassenpflug (Hamburg, Germany)C. von Auer (Mainz, Germany) -
Investigating the pathomolecular mechanisms an in-frame heterozygous von Willebrand factor large deletion in a von Willebrand disease patient with significant bleeding history
H. Yadegari1, N. Marquardt1, V. Ivaskevicius1, O. Rawley2, L. Swystun2, D. Lillicrap2, J. Oldenburg1 (1Bonn, Germany, 2Kingston, Canada)
-
Possible role of protein disulfide isomerase PDIA1 in mechanisms of von Willebrand disease type 3
M. A. Brehm, S. Vollmers, T. Obser, R. Schneppenheim (Hamburg, Germany)
-
Synergistic effects of a procoagulant bispecific antibody and rescue therapy on thrombin generation - a potential safety risk?
R. Hartmann1, S. Knappe1, B. Goldstein2, B. Ewenstein2, L. Valentino3, F. Scheiflinger1 (1Vienna, Austria, 2Cambridge, United States, 3Bannockbum, United States)
-
Calcium binding sites of coagulation factor XIII (FXIII) A subunit and their functional relevance to the activation of FXIII A subunit
S. Singh1, C. Krettler2, C. Reinhart 2, J. Dodt 3, V. Ivaskevicius 1, J. Oldenburg 1, A. Biswas1 (1Bonn, Germany, 2Frankfurt, Germany, 3Langen, Germany)
-
Hemophilia macrophages exhibit specific defects relating to wound healing
J. Pilch, D. Lessig, M. Bernard, E. C. Schwarz, H. Eichler, L. M. Knowles (Homburg, Germany)
-
Plasma derived FVIII concentrates induce neutrophil activation and neutrophil extracellular trap formation.
B. E. Kehrel, A. Bertling, M. F. Brodde (Muenster, Germany)
-
Chairs:
M. Albisetti Pedroni (Zurich, Switzerland)R. Knöfler (Dresden, Germany) -
Thrombophilia in pediatric cancer
A. C. Chan (Hamilton, Canada)
-
Thrombophilia screening in adolescents
U. Nowak-Göttl (Kiel, Germany)
-
Cerebral venous thrombosis in neonates, children and adolescents; results from the German pediatric surveillance unit for rare pediatric diseases (ESPED)
S. Holzhauer 1, K. Kentouche 2, A. Kruempel 3, C. Heller 4, R. Knoefler5, R. Straeter6, U. Nowak-Göttl 7 (1Berlin , Germany , 2Jena , Germany , 3Muenster, Germany , 4Frankfurt, Germany , 5Dresden , Germany , 6Muenster , Germany , 7Kiel , Germany )
-
Faster spatial fibrin clot formation in neonates than in adults.
A. Schlagenhauf, S. Pohl, E. Zoehrer, B. Leschnik, H. Haidl, S. Gallistl, W. Muntean (Graz, Austria)
-
Chairs:
M. Gawaz (Tuebingen, Germany)A. Zirlik (Freiburg, Germany) -
Early atheroprotection through fostamatinib fails in established disease when local macrophage proliferation dominates lesion progression
C. Härdtner1, A. Lindau1, B. Dufner1, N. Hoppe1, F. K. Swirski2, P. Libby2, C. S. Robbins3, C. Bode1, A. Zirlik1, I. Hilgendorf1 (1Freiburg, Germany, 2Boston, USA, 3Toronto, Canada)
-
The role of the purinergic receptor P2X7 in the pathogenesis of atherosclerosis
S. von Garlen, A. Heidenreich, P. Stachon, J. Merz, S. Geis, B. Dufner, N. Hoppe, N. Anto Michel, C. Bode, M. Idzko, A. Zirlik (Freiburg, Germany)
-
Targeting coagulation factor Xa with rivaroxaban reduces the onset and progression of atherosclerosis and enhances plaque stability in ApoE null mice
J. Posthuma1, J. Posma1, R. van Gorp1, A. Jaminon1, P. Leenders1, R. van Oerle1, S. Heitmeier2, L. Schurgers1, H. ten Cate1, H. Spronk1 (1Maastricht, The Netherlands, 2Wuppertal, Germany)
-
MicroRNA-23a regulates the tissue factor alternative splicing and thrombogenicity
T. Tabaraie, M. Witkowski, J. Friebel, A. Doerner, U. Landmesser, U. Rauch (Berlin, Germany)
-
ADAMTS13 activity, neutrophil extracellular traps(NETs) and platelet functional capacity in patients with strokes from different etiologies.
H. S. Bölting, M. Rumpf, R. Dittrich, J. Minnerup, L. Schuengel, M. F. Brodde, M. Ritter, B. E. Kehrel (Muenster, Germany)
-
The cross talk between coagulation cascade and endothelial cells in a porcine limb ischemia reperfusion injury model and the protective role of C1-INH
M. Abdelhafez, J. Shaw, D. Sutter, J. Schnider, H. Jenni, E. Voegelin, M. Constantinescu, R. Rieben (Bern, Switzerland)
-
Chairs:
A. Huth-Kühne (Heidelberg, Germany)W. Schramm (Munich, Germany) -
Management of cardiovascular disease in aging patients with hemophilia
R. Schutgens (Utrecht, The Netherlands)
-
Treatment of hepatitis C - what the hemostasiologist should know
J.-F. Dufour (Bern, Switzerland)
-
Value of factor prophylaxis in elderly patients with hemophilia
J. Oldenburg (Bonn, Germany)
-
Chairs:
J. Beyer-Westendorf (Dresden, Germany)S. Schellong (Dresden, Germany) -
DOACs dose adherence during initial and long term VTE management. Practical implications, findings from the RIETE registry.
E. Papadakis1, J. Trujillo-Santos2, P. Di Micco3, F. Dentali4, J.-A. Diaz-Peromingo5, M.-J. Nunez6, I. Canas7, D. Mastroiacovo8, M.-S. De Sousa9, A. Banti1, M. Monreal10 (1Thessaloniki, Greece, 2Murcia, Spain, 3Naples, Italy, 4Varese, Italy, 5Santiago de Compostela, Spain, 6Pontevedra, Spain, 7Barcelona, Spain, 8Avezzano, Italy, 9Vila Nova de Gaia, Portugal, 10Badalona, Spain)
-
Patterns of VTE treatment with rivaroxaban in cancer patients Results of the prospective Dresden NOAC registry (NCT01588119)
S. Endig, S. Marten, A. Reitter, K. Daschkow, L. Tittl, J. Beyer-Westendorf (Dresden, Germany)
-
Survival and recurrent venous thromboembolism in 834 subjects after a first episode of isolated distal or proximal deep vein thrombosis without pulmonary embolism
S. Barco1, M. Corti2, A. Trinchero1, C. Picchi2, S.V. Konstantinides1, C. Ambaglio2, F. Dentali3, M. Barone2 (1Mainz, Germany, 2Pavia, Italy, 3Varese, Italy)
-
Clinical outcomes of a management strategy consisting of tailored anticoagulant treatment based on residual vein thrombosis: contemporary data
M. Nagler1, H. ten Cate2,3, M. Prins2, A. ten Cate-Hoek2 (1Bern, Switzerland, 2Maastricht, The Netherlands, 3Maastricht , The Netherlands)
-
Innate effector-memory T cell activation regulates post-thrombotic vein wall inflammation and thrombus resolution
F. Shahneh, N. Luther, M. Brähler, F. Krebs, S. Jäckel, P. Wenzel, K. Schäfer, C. Becker (Mainz, Germany)
-
Genotype phenotype association in a large cohort of subjects with protein C or protein S deficiency
L. Böff1, F. Bergmann2, A. Czwalinna2, C. Heller1, M. Krause3, W. Miesbach1, S. Körber1, E. Seifried1, C. Geisen1 (1Frankfurt / Main, Germany, 2Hannover, Germany, 3Wiesbaden, Germany)
-
Chairs:
A. Angelillo-Scherrer (Bern, Switzerland)B. Zieger (Freiburg, Germany) -
Diagnosis and management of immune thrombocytopenia in childhood
Journal article „Hämostaseologie“T. Kühne (Basel, Switzerland)
-
How a protein becomes an autoantigen, lessons learned from HIT
A. Greinacher (Greifswald, Germany)
-
Chairs:
K. Holstein (Hamburg, Germany)Unter der Mitwirkung der aufgelisteten Referenten werden Fälle aus der Praxis und die verschiedenen Behandlungsoptionen diskutiert.M. Bernateck (Hanover, Germany)
C. Gura (Berlin, Germany)
P. Pennekamp (Cologne, Germany)
A. Tiede (Hanover, Germany)Chairs:
C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)K. Kentouche (Jena, Germany)Many new factor concentrates what to know and consider before switchingC. Male (Vienna, Austria)
New FVIII and FIX products laboratory requirementsB. Pötzsch (Bonn, Germany)
Possibilities to rebalance hemostasis in hemophiliaA. Angelillo-Scherrer (Bern, Switzerland)
Chairs:
B. Kemkes-Matthes (Giessen, Germany)H. ten Cate (Maastricht, The Netherlands)Rivaroxaban or fondaparinux for superficial-vein thrombosis - a randomized controlled non-inferiority trialJ. Beyer-Westendorf1,2, S. Schellong1, H. Gerlach3, E. Rabe4, J. Weitz5, K. Jersemann1, K. Sahin6, R. Bauersachs7,8 (1Dresden, Germany, 2London, UK, 3Mannheim, Germany, 4Bonn, Germany, 5Hamilton, Ontario, Canada, 6Cologne, Germany, 7Darmstadt, Germany, 8Mainz, Germany)
Thrombophilia screening - Which patients, when, and what is appropriateE. Lindhoff-Last (Frankfurt am Main, Germany)
How to reverse anticoagulaion - options for vitamin K antagonists and DOACsS. Eichinger-Hasenauer (Vienna, Austria)
Chairs:
W. Eberl (Braunschweig, Germany)U. Scholz (Leipzig, Germany)Clinical PearlM. Albisetti Pedroni (Zurich, Switzerland)
The staphylococcal toxin Panton-Valentine Leukocidin induces neutrophil extracellular trap (NET) formation that leads to platelet activation.M. F. Brodde1, A. Bertling1, S. Niemann1, A. C. Fender2, H. Van de Vyver1, B. Schlott3, C. Heilmann1, G. Peters1, B. Löffler3, B. E. Kehrel1 (1Muenster, Germany, 2Duesseldorf, Germany, 3Jena, Germany)
Prothrombin fragment F1+2 in pregnancy is associated with thrombophilic risk factors and a history of venous thromboembolism (VTE)R. B. Zotz1, R. E. Scharf1, A. Gerhardt2,1 (1Duesseldorf, Germany, 2Ulm, Germany)
Chairs:
F. Langer (Hamburg, Germany)M. Nagler (Bern, Switzerland)Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodiesB. Pezeshkpoor, A.-C. Berkemeier, J. Müller, T. Albert, J. Oldenburg (Bonn, Germany)
Blood clotting supports glioma invasion and colonizationJ. Pilch, A. Burkardt, C. Wolter, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, L. M. Knowles (Homburg, Germany)
rVIII-SingleChain: Results of a Phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia AI. Pabinger1, O. Stasyshyn2, G. Iosava3, C. Djambas Khayat4, J. Ong5, K. Fischer6, F. Abdul Karim7, A. Veldman8, K. St. Ledger9 (1Vienna, Austria, 2Lviv, Ukraine, 3Tbilisi, Georgia, 4Beirut, Lebanon, 5Davao, Philippines, 6Ultrecht, Netherlands, 7Jalan Tun Razak, Kuala Lumpur, Malaysia, 8Marburg, Germany, 9King of Prussia, PA, United States)
Comparison of biomarkers and immunological parameters between hemophilia patients, rheumatoid arthritis patients, and control subjectsR. Toenges1, A. Wittenbrinck1, S. Gundermann1, M. Wahle2, R. Schäfer1, W. Miesbach1 (1Frankfurt am Main, Germany, 2Augsburg, Germany)
Activation and Inactivation of rVIII-SingleChainC. Horn, H. J. Metzner (Marburg, Germany)
Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber diseaseR. Gindele1, T. Major2, Z. Szabo1, K. B. Kovács1, G. Pfliegler1, Z. Bereczky1 (1Debrecen, Hungary, 2Eger, Hungary)
The special role of anti-ADAMTS13-IgA in acquired TTP: Production induced by infectious microorganisms?I. Scharrer, J. Falk (Mainz, Germany)
Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficienciesM. Nagy1, T. G. Mastenbroek1, N. J. A. Mattheij1, S. de Witt1, K. J. Clemetson2, J. Kirschner3, A. S. Schulz4, J. M. E. M. Cosemans1, B. Zieger3, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bern, Switzerland, 3Freiburg, Germany, 4Ulm, Germany)
Development and application of methods for the selective measurement of the human single amino acid exchange variant factor IX PaduaA. Weber1, A. Engelmaier1, D. Voelkel2, R. Pachlinger2, F. Scheiflinger1, H. Rottensteiner1 (1Vienna, Austria, 2Orth, Austria)
Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII productA. Weber, S. Haindl, G. Mohr, A. Engelmaier (Vienna, Austria)
Chairs:
L. Alberio (Lausanne, Switzerland)C. Mannhalter (Vienna, Austria)Highlight: Platelet granules - secretory and secretiveK. Jurk (Mainz, Germany)
Clinical Pearl: Inherited thrombocytopenia due to ANKRD26 mutationJ. Rufener (Bern, Switzerland)
Phospholipase D1 is a regulator of inflammatory platelet-endothelial interactions under high shear conditionsM. Klier1, N. Gowert1, S. Jäckel2, C. Reinhardt2, M. Elvers1 (1Düsseldorf, Germany, 2Mainz, Germany)
Heterogeneous regulation of platelet adhesive-receptor shedding in thrombus formationC. C. F. M. J. Baaten1, F. Swieringa1, T. Misztal2, T. G. Mastenbroek1, M. A. H. Feijge1, M. M. P. C. Donners1, P. W. Collins3, P. E. J. van der Meijden1, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bialystok, Poland, 3Cardiff, United Kingdom)
Chairs:
R. Bauersachs (Darmstadt, Germany)V. Hach-Wunderle (Frankfurt am Main, Germany)Wie setzt man die oralen Antikoagulanzien am besten ein?C.-E. Dempfle (Mannheim-Lindenhof, Germany)
Antikoagulation und SchlaganfallprophylaxeM. Moser (Freiburg, Germany)
Behandlung und Rezidivprophylaxe von VTER. Bauersachs (Darmstadt, Germany)
Chairs:
A. Greinacher (Greifswald, Germany)Einführung und BegrüssungA. Greinacher (Greifswald, Germany)
HIT - im Alltag relevant?E. Lindhoff-Last (Frankfurt am Main, Germany)
HIT? HIT! Vom Verdacht zur DiagnoseT. Bakchoul (Tuebingen, Germany)
Therapieansätze beim HIT-PatientenA. Greinacher (Greifswald, Germany)
Der HIT-Patient in der PraxisJ. H. Beer (Baden, Switzerland)
Chairs:
A. Tiede (Hanover, Germany)Begrüssung und EinleitungA. Tiede (Hanover, Germany)
Die individualisierte Therapie bei erworbener Hemmkörper HämophilieP. Knöbl (Vienna, Austria)
40 Jahre FEIBA: Erfahrungen während der ITIJ. Oldenburg (Bonn, Germany)
Bypassing Agenzien während der ITI: Interim Analyse der ObsITI StudieC. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)
Chairs:
A. Huth-Kühne (Heidelberg, Germany)R. Knöfler (Dresden, Germany)EinführungPharmakokinetik in der Hämophilie-TherapieD. Garmann (Wuppertal, Germany)
Faktor VIII im Labor - eine Frage des AssaysJ. Müller (Bonn, Germany)
Ein Jahr Kovaltry - Erfahrungen aus der klinischen Praxis mit pädiatrischen PatientenC. Bidlingmaier (Munich, Germany)
Ein Jahr Kovaltry - Erfahrungen aus der klinischen Praxis mit erwachsenen PatientenG. Goldmann (Bonn, Germany)
Chairs:
M. Spannagl (Munich, Germany)Umfelddiagnostik bei spontanen ThrombosenF. Langer (Hamburg, Germany)
Thrombosen bei hämatologischen ErkrankungenH. K. Al-Ali (Halle, Germany)
Fallbeispiel atypische Thrombosen bei PNHJ. Chromik (Frankfurt am Main, Germany)
Chairs:
K. Clemetson (Bern, Switzerland)J. Oldenburg (Bonn, Germany)Therapeutic genome editing with engineered nucleases
Journal article „Hämostaseologie“T. Cathomen (Freiburg, Germany)
Phenotypic disorder profiling and next generation sequencing in bleeding disordersW. H. Ouwehand (Cambridge, United Kingdom)
Blood clotting supports glioma invasion and colonizationJ. Pilch, A. Burkardt, C. Wolter, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, L. M. Knowles (Homburg, Germany)
Improved values regarding acquired von Willebrand syndrome in patients with HeartMate III compared to HeartMate IIU. Geisen1, K. Brehm1, G. Trummer1, F. Beyersdorf1, M. Berchtold-Herz1, C. Heilmann1, J. Schelling1, A. Schlagenhauf2, B. Zieger1 (1Freiburg, Germany, 2Graz, Austria)
Reconstituted whole blood using fresh frozen plasma versus coagulation factor concentrates: an in vitro studyG. E. Iapichino1,2, M. Ponschab1,3, C. J. Schlimp1,4, S. Süssner5, J. Cadamuro6, H. Redl1, H. Schöchl1,6 (1Vienna, Austria, 2Milan, Italy, 3Linz, Austria, 4Edinburgh, United Kingdom, 5 Linz, Austria, 6Salzburg, Austria)
Hemostatic potential of reconstituted whole blood using fresh frozen plasma versus increasing concentration of lyoplasmaG. E. Iapichino1,2, M. Ponschab1,3, C. J. Schlimp1,4, C. Gabriel3, J. Cadamuro5, H. Redl1, H. Schöchl1,5 (1Vienna, Austria, 2Milan, Italy, 3Linz, Austria, 4Edinburgh, United Kingdom, 5Salzburg, Austria)
Trend in Hospital Cases of Acquired Hemophilia A (AHA) 2010 - 2014 in GermanyS. Wahler1, A. Tiede2 (1Hamburg, Germany, 2Hannover, Germany)
Procoagulant microparticles and nanoparticles from whole blood reconstituted with age-different blood components.M. Ponschab1,2, C. J. Schlimp1,3, L. Wisgrill1, A. Spittler1, C. Gabriel2, J. Zipperle1, G. E. Iapichino1,4, H. Redl1, H. Schöchl1,5 (1Vienna, Austria, 2Linz, Austria, 3Edinburgh, United Kingdom, 4Milan, Italy, 5Salzburg, Austria)
Longitudinal analyses of microparticle-associated tissue factor activity and venous thromboembolism (VTE) in cancer patientsE.-M. Reitter, A. Kaider, C. Ay, J. Thaler, C. Marosi, I. Pabinger (Vienna, Austria)
Thrombin formation capacity in patients with two different left-ventricular assist devices and after heart transplantationA. Schlagenhauf1, U. Geisen2, K. Brehm2, G. Trummer2, F. Beyersdorf2, M. Berchtold-Herz2, B. Zieger2 (1Graz, Austria, 2Freiburg, Germany)
Chronic disseminated intravascular coagulation in a patient with antiphospholipid antibodies and acquired protein S deficiencyC. Dicke, K. Holstein, M. Voigtländer, F. Stahl, U. Schnoor, C. Bokemeyer, F. Langer (Hamburg, Germany)
Successful inhibitor eradication with ofatumumab in a patient with acquired hemophilia AR. Fischer, M. Alrifai, K. Heidinger, B. Kemkes-Matthes (Giessen, Germany)
Is a too low plasminogen level in the plasma of kidney transplant recipients the reason of irreversable rejection reactions?H. E. Karges (Marburg, Germany)
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on chronic hemodialysis: results of the VIVALDI studyO. Königsbrügge, E. Grilz, I. Pabinger, M. Säemann, C. Ay (Vienna, Austria)
Dual mechanical assistance with veno-arterial extracorporeal membrane oxygenation and percutaneous continuous-flow device: double trouble for von Willebrand factorA. Rauch, F. Vincent, E. Jeanpierre, C. Caron, A. Dupont, N. Rousse, A. Vincentelli, E. Robin, E. Van Belle, J. Goudemand, S. Susen (Lille, France)
Direct oral thrombin inhibitor dabigatran etexilate is able to controle chronic disseminated intravasal coagulation: a case reportW. Korte, L. Graf (1St. Gallen, Switzerland)
Management of epidural bleeding in a patient with acquired hemophilia A masked by phenprocoumon therapyM. Alrifai, R. Fischer, K. Heidinger, B. Kemkes-Matthes (Giessen, Germany)
Differential effects of novel anticoagulants: fXa versus fIIa inhibition on coagulation and inflammationS. Nazir1, K. Shahzad1, I. Gadi1, M. Al-Dabet1, S. Kohli1, S. Ranjan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)
How to assess in vivo anticoagulant effect of RivaroxabanD. Bertaggia Calderara1, D. Kröll2, C. Gerschheimer1, N. Nicolas1, G. Stirnimann2, L. Alberio1 (1Lausanne, Switzerland, 2Bern, Switzerland)
Single-center experience with thrombolysis in high- and intermediate-risk pulmonary embolismN. Herr, C. Bode, T. Wengenmayer, D. Duerschmied (Freiburg, Germany)
Real life efficacy and safety of edoxaban for stroke prevention in atrial fibrillation Results of the prospective NOAC registry (NCT01588119)L. Tittl, J. Hecker, L. Wunder, T. Schreier, A. Reitter, J. Beyer-Westendorf (Dresden, Germany)
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physiciansN. Mumoli1, S. Barco2, M. Cei3, M. Giorgi-Pierfranceschi3, M. Campanini4, A. Fontanella5, W. Ageno6, F. Dentali6 (1Livorno, Italy, 2Mainz, Germany, 3Piacenza, Italy, 4Novara, Italy, 5Napoli, Italy, 6Varese, Italy)
CONKO-011: Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients a randomized phase III studyM. Sinn1, A. Jühling1, J. Heinz2, M. Hellmann3, R. U. Trappe4, T. Südhoff5, B. Günther6, L. Wislocka1, J. Striefler1, U. Pelzer1, H. Riess1 (1Berlin, Germany, 2Freiburg, Germany, 3Köln , Germany, 4Bremen, Germany, 5Passau, Germany, 6Düsseldorf, Germany)
Long-term clinical outcomes of patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists: A prospective, multicenter cohort study of elderly patients with venous thromboembolism.M. Nagler1, A. Angelillo-Scherrer1, M. Mean1, A. Limacher1, C. Abbal2, M. Righini3, H.-J. Beer4, J. Osterwalder5, B. Frauchiger6, M. Aschwanden7, C. Matter8, N. Kucher1, J. Cornuz2, M. Banyai9, M. Husmann8, D. Staub7, L. Mazzolai2, O. Hugli2, N. Rodondi1, D. Aujesky1 (1Bern, Switzerland, 2Lausanne, Switzerland, 3Geneva, Switzerland, 4Baden, Switzerland, 5St. Gallen, Switzerland, 6Frauenfeld, Switzerland, 7Basel, Switzerland, 8Zurich, Switzerland, 9Lucerne, Switzerland)
Clinical observations on potential interactions of phenprocoumon, colchicine and rivaroxaban in a patient with compound homozygosity for FV Leiden and familial Mediterranean fever (FMF, M680I).L. Graf, K. Jung, W. Korte (1St. Gallen, Switzerland)
Activation of neutrophils - but not endothelial cells - is regulated by serotonin during myocardial reperfusion injuryM. Mauler, F. Glatzki, N. Herr, C. Schoenichen, T. Witsch, D. Stallmann, C. Bode, I. Ahrens, I. Hilgendorf, D. Duerschmied (Freiburg, Germany)
Protein C and factor X activities from patients with ischemic stroke and type II diabetes mellitus.O. Kravchenko, O. Savchuk, T. Tsarenko, L. Ostapchenko (Kiev, Ukraine)
Inhibition of coagulation factor Xa attenuates myocardial ischemia reperfusion injury in miceJ. J. Posma, J. J. Posthuma, R. Van Oerle, H. Ten Cate, H. H. Spronk (Maastricht, Netherlands)
Idiopathic catastrophic thrombosis with happy end - a case reportJ. Heid, H. A. Katus, O. Müller (Heidelberg, Germany)
The molecular etiology and pathophysiology of platelet-mediated aspirin responsive erythromelalgia and microascular thrombosis in JAK2, CALR and MPL mutated thrombocythemiaJ. J. Michiels1,2 (1Antwerp, Belgium, 2Rotterdam, The Netherlands)
Effect of alpha-2 plasmin inhibitor p.Arg6Trp polymorphism and antigen level on the risk of myocardial infarction in young patientsE. Katona, A. Orosz, Z. Mezei, L. Balogh, Z. Bereczky, I. Edes, L. Muszbek (Debrecen, Hungary)
rVIII-SingleChain: results of a phase III PK, efficacy and safety study in children less than 12 years of age with severe hemophilia AI. Pabinger1, O. Stasyshyn2, G. Iosava3, C. Djambas Khayat4, J. Ong5, K. Fischer6, F. Abdul Karim7, A. Veldman8, K. St. Ledger9 (1Vienna, Austria, 2Lviv, Ukraine, 3Tbilisi, Georgia, 4Beirut, Lebanon, 5Davao, Philippines, 6Ultrecht, Netherlands, 7Kuala Lumpur, Malaysia, 8Marburg, Germany, 9King of Prussia, PA, United States)
Comparison of biomarkers and immunological parameters between hemophilia patients, rheumatoid arthritis patients, and control subjectsR. Toenges1, A. Wittenbrinck1, S. Gundermann1, M. Wahle2, R. Schäfer1, W. Miesbach1 (1Frankfurt am Main, Germany, 2Augsburg, Germany)
Introduction of a guideline for the treatment of synovitis in patients with hemophiliaB. Habermann1, A. Seuser2, T. Hilberg3 (1Mainz, Germany, 2Bonn, Germany, 3Wuppertal, Germany)
The coagulation Factor XIII (FXIII) A subunit activation peptide directs the evolution of FXIIIA as a proteolytically activated dimeric moleculeA. Biswas, S. Singh, V. Ivaskevicius , J. Oldenburg (Bonn, Germany)
FSAP and altered fibrin clot structure: Is there a link to FXIII?M. Etscheid, N. Beer, R. Seitz, J. Dodt (Langen, Germany)
Amidolytic thrombin activity under the ischemic stroke peptide pool influenceT. Katrii, O. Savchuk (Kiev, Ukraine)
What hemophilia patients expect from the new extended half-life (EHL) products and their willingness to switch - Results from the DACH regionS. von Mackensen1, W. Kalnins1, L. Hostettler2, J. Krucker2, M. Albisetti3, J. Weiss4, I. Pabinger4, J. Oldenburg5 (1Hamburg, Germany, 2Altstätten, Switzerland, 3Zurich, Switzerland, 4Vienna, Austria, 5Bonn, Germany)
Monitoring of perioperative factor VIII treatment in a remote hospital by electronic diary smart medicationTMW. Mondorf, D. Schmoldt (1Frankfurt am Main, Deutschland)
An Asp94Gly missense mutation in GP1BB causes severe Bernard-Soulier syndrome in an Iraqi familyD. Boeckelmann, E. Lerner, J. Schelling, K. Neubauer, K. Sandrock-Lang, B. Zieger (Freiburg, Germany)
Impact of maintaining higher FVIII trough levels with BAX 855: Rationale and design of the PROPEL studyH.-Y. Lee1, B. E. Abbuehl2, A. Hafeman3, W. Engl2, L. Patrone3, L. A. Valentino4, B. M. Ewenstein5 (1Zurich, Switzerland, 2Vienna, Austria, 3Westlake Village, CA, United States, 4Chicago, IL, United States, 5Cambridge, MA, United States)
Nonacog beta pegol in adult and paediatric patients: pooled data from the paradigm^TM clinical programmeJ. Oldenburg1, M. Carcao2, S. R. Lentz3, J. Mahlangu4, M. Mancuso5, T. Matshushita6, C. Négrier7, W. H. Ong Clausen8, S. Ehrenforth8, G. Young9 (1Bonn, Germany, 2Toronto, Canada, 3Iowa, United States, 4Johannesburg, South Africa, 5Milan, Italy, 6Nagoya, Japan, 7Lyon, France, 8Søborg, Denmark, 9Los Angeles, United States)
Challenges in immune tolerance induction in an adult patient with non-severe hemophilia A.P. Kuta1, S. Achenbach1, T. Zöller2, R. Zimmermann1 (1Erlangen, Germany, 2Coburg, Germany)
Prevalence of overweight and obesity in children, adolescents and young adults with severe hemophilia A results of 3 German pediatric hemophilia treatment centersM. Olivieri1, C. Königs2, S. Horneff3, C. Bidlingmaier1 (1Munich, Germany, 2Frankfurt, Germany, 3Bonn, Germany)
Pharmacokinetic results of two studies with a novel fibrinogen concentrate in subjects with afibrinogenaemia.W. Stevens1, A. Bellon1, F. Bridey1, Ph. de Moerloose2 (1Les Ulis, France, 2Geneva, Switzerland)
Pitfalls in carrier testing of haemophilia AB. Preisler1, I. Radermacher1, I. Schwarze1, R. Kuhlemann1, R. Maurer1, J. Beckedahl1, L. Rothbrust1, J. Junen1, U. Scholz2, B. Pezeshkpoor1, A. Pavlova1, J. Oldenburg1 (1Bonn, Germany, 2Leipzig, Germany)
Long-term use of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia BS. Halimeh1, A. Lubetsky2, U. Martinowitz2, T. Lissitchkov3, A. Veldman4, E. Santagostino5 (1Duisberg, Germany, 2Tel Hashomer, Israel, 3Sofia, Bulgaria, 4Marburg, Germany, 5Milan, Italy)
Resolution of target joints during once-weekly prophylaxis with rIX-FP in patients with hemophilia BH. J. Laws1, H. Hanabusa2, C. Négrier3, T. Lissitchkov4, G. Castaman5,6, A. Tagliaferri7, K. Fukutake2, M. F. López Fernández8, A. Veldman9, E. Santagostino10 (1Dusseldorf, Germany, 2Tokyo, Japan, 3Lyon, France, 4Sofia, Bulgaria, 5Vicenza, Italy, 6Florence, Italy, 7Parma, Italy, 8La Coruna, Spain, 9Marburg, Germany, 10Milan, Italy)
Epidemiological insights about hemophilia B by analysis of German hospital quality reportsS. Wahler1, A. Müller2 (1Hamburg, Germany, 2München, Germany)
Efficacy and safety of a VWF/FVIII concentrate in surgical procedures results from the ongoing study Wilate-STATES. Halimeh1, M. Daoud1, M. Rieke2, T. Lang2, J. Kadar3, S. Alesci4, J. Koscielny5, J. Feddern6, S. Seeger6 (1Duisburg, Germany, 2Hohne, Germany, 3Cologne, Germany, 4Bad Homburg, Germany, 5Berlin, Germany, 6Langenfeld, Germany)
Combined congenital deficiency of coagulation factors VII and X in two siblings with heterozygous factor V Leiden mutation (R506Q)K. Heidinger1, R. Fischer1, M. Alrifai1, A. Pavlova2, B. Kemkes-Matthes1 (1Gießen, Germany, 2Bonn , Germany)
Efficacy and safety of rVIII-SingleChain in 21 major surgeriesJ. Oldenburg1, C. Djambas Khayat2, J. Mahlangu3, R. Baker4, C. Leissinger5, E. Santagostino6, M. F. Lopez-Fernandez7, F. Abdul Karim8, A. Veldman9, K. St. Ledger10, I. Pabinger11 (1Bonn, Germany, 2Beirut, Lebanon, 3Johannesburg, South Africa, 4Nedlands, Australia, 5New Orleans, United States, 6Milan, Italy, 7La Coruña, Spain, 8Jalan Tun Razak, Kuala Lumpur, Malaysia, 9Marburg, Germany, 10King of Prussia, United States, 11Vienna, Austria)
A preliminary study to find novel interaction partners for the coagulation factor XIII (FXIII) B subunit free formS. Singh1, J. Dodt2, A. Reuter2, V. Ivaskevicius1, J. Oldenburg1, A. Biswas1 (1Bonn, Germany, 2Langen, Germany)
Determining the causality of heterozygous missense mutations detected in F13A1 and F13B genes and reported from patients with mild coagulation factor XIII (FXIII) deficiencyA. Biswas1, A. Thomas1, J. Dodt2, H. Philippou3, E. Heathershaw3, H. E. Jürgen1, V. Ivaskevicius1, J. Oldenburg1 (1Bonn, Germany, 2Langen, Germany, 3Leeds, UK)
Annual Bleeding vs. factor VIII/IX consumption comparison of result in 2014 and 2015 according to electronic diary smart-medicationTMR. Fischer1, H. Eichler2, K. Holstein3, R. Klamroth4, A. Nimtz-Talaska5, H. Richter6, K. Severin7, C. Wermes8, W. Mondorf9 (1Giessen, Deutschland, 2Homburg/Saar, Deutschland, 3Hamburg, Deutschland, 4Berlin, Deutschland, 5Frankfurt an der Oder, Deutschland, 6Münster Westfalen, Deutschland, 7Köln, Deuschland, 8Hannover, Deutschland, 9Frankfurt am Main, Deutschland)
The regulatory profile of the 5´ untranslated region of F13A1 gene of coagulation factor XIII (FXIII) A subunitM. A. Jamil, S. Singh, V. Ivaskevicius, O. El-Maarri, J. Oldenburg, A. Biswas (Bonn, Germany)
Long-term immunogenicity, safety and efficacy of human-cl rhFVIII in previously treated children with severe hemophilia AJ. Bichler1, A. Klukowska2, V. Vdovin3, T. Szczepanski4, I. Dzhunova1, R. Liesner5 (1Lachen, Switzerland, 2Warsaw, Poland, 3Moscow, Russian Federation, 4Katowice, Poland, 5London, United Kingdom)
Individualized prophylaxis with Nuwiq® (Human-cl rhFVIII) in adult PTPs with severe hemophilia AJ. Bichler1, C. Kessler2, K. Meijer3, A. Armstrong4, S. Knaub1, G. Pezeshki5, M. Wang6 (1Lachen, Switzerland, 2Washington DC, USA, 3Groningen, The Netherlands, 4Helsinki, Finland, 5Hoboken, NJ, USA, 6Aurora, CO, USA)
Efficacy and safety of Nuwiq® in clinical trials with previously treated patients with severe hemophilia AR. Klamroth1, J. Bichler2, M. Jansen3, L. Belyanskaya2, S. Knaub2, R. Liesner4, J. Oldenburg5, A. Tiede6, C. Kessler7 (1Berlin, Germany, 2Lachen, Switzerland, 3Vienna, Austria, 4London, United Kingdom, 5Bonn, Germany, 6Hannover, Germany, 7Washington DC, USA)
Interim bleeding data of 522 hemophilia A patients from the international AHEAD Study after 3 years of observationK. Steinitz-Trost1, J. Oldenburg2, D. A. Tsakiris3, C. Hermans4, K. Khair5, R. Liesner5, M. G. Mazzucconi6, G. Spotts7, A. J. Reininger1, A. Gringeri1 (1Vienna, Austria, 2Bonn, Germany, 3Basel, Switzerland, 4Brussels, Belgium, 5London, United Kingdom, 6Rome, Italy, 7Westlake Village, USA)
Feiba global outcome study (FEIBA-GO): first demographic data from a real world study on FEIBA in patients with inhibitorsK. Steinitz-Trost1, C. Escuriola Ettingshausen2, C. Hermans3, P. A. Holme4, C. Negrier5, S. Rangarajan6, A. Rocino7, J. Windyga8, A. Gringeri1, R. Crea1, A. R. Cid9 (1Vienna, Austria, 2Frankfurt-Moerfelden, Germany, 3Brussels, Belgium, 4Oslo, Norway, 5Bron, France, 6Basingstoke, United Kingdom, 7Naples, Italy, 8Warsaw, Poland, 9Valencia, Spain)
Inhibitor development in previously untreated patients with severe hemophilia A treated with human-cl rhFVIII, a new generation recombinant FVIII of human originA. Russo1, C. Altisent2, A. Borel-Derlon3, H. Chambost4, M. Gattens5, Y. Gruel6, A. Klukowska7, C. Koenigs8, T. Lambert9, R. J. Liesner10, M. Sigaud11, M. Abashidze12, O. Aleinkova13, M. J. Belletrutti14, M. Carcao15, A. K. C. Chan16, L. Dubey17, J. Ducore18, N. A. Fouzia19, N. Kavardakova20, M. El Khorassani21, S. Lohade22, V. Turea23, J. K. M. Wu24, V. Vdovin25 (1Mainz, Germany, 2Barcelona, Spain, 3Caen, France, 4Marseille, France, 5Cambridge, United Kingdom, 6Tours, France, 7Warsaw, Poland, 8Frankfurt 618 elden-Walldorf, Germany ck1, S. Gundermann1, M. Wahle2, R. Schäfer1, W. Miesbach1 (1Frankfurt am Main, Germany, 2Augsburg, Germany) m Main, Germany, 9Le Kremlin Bicetre, France, 10London, United Kingdom, 11Nantes, France, 12Tbilisi, Georgia, 13Minsk, Belarus, 14Edmonton, Canada, 15Toronto, Canada, 16Hamilton, Canada, 17Lviv, Ukraine, 18Sacramento, US, 19Vellore, India, 20Kiev, Ukraine)
Autologous serum infusion induces no thrombin formation but generation of activated protein CC. Berens, H. Rühl, J. Rossa, A. Winterhagen, J. Oldenburg, J. Müller, B. Pötzsch (Bonn, Germany)
Treatment of acquired hemophilia A with recombinant porcine FVIII in GermanyC. Hart1, A. Huth-Kühne2, R. Klamroth3, M. Angstwurm4, M. Stemberger4, M. Spannagl4 (1Regensburg, Germany, 2Heidelberg, Germany, 3Berlin, Germany, 4München, Germany)
Pulmonary embolism in a patient with severe factor VII deficiency after femoral neck fracture despite thromboprophylaxis with low-molecular-weight heparinK. Holstein, M. Voigtländer, C. Dicke, F. Langer (Hamburg, Germany)
Genetic therapy for hemophilia: Whats new?M.-K. Holz1, K. Waack-Buchholz1, D. Reinhardt1, H. Hanenberg2 (1Essen, Germany, 2Düsseldorf, Germany)
In-vitro analysis of siRNA based inhibition of function of activated protein C (APC): Towards an alternative therapeutic option for hemophilia.D. Mirgal1, V. Pujari1, K. Ghosh2, S. Shetty1 (1Mumbai, Maharashtra, 2Surat,Gujrath, India)
Novel insights in the molecular etiology of recessive von Willebrand disease 2N due to DD3 Factor VIII-binding site mutations of von Willebrand factorJ. J. Michiels1,2, F. Hansen3, R. Dingle3, A. Batorova4, T. Prigancova4, P. Smejkal5, M. Penka5, I. Vangenechten1, A. Gadisseur1 (1Edegem, Belgium, 2Rotterdam, Netherlands, 3London, United Kingdom, 4Bratislava, Slovakia, 5Brno, Czech Republic)
Protein S and purpura fulminans: Whats new?R. Prince1, S. Calzavarini 1, M. Yasuhiro2, J. H. Griffin 3, J. A. Fernández3, F. Saller 4, A. Angelillo-Scherrer1 (1Bern, Switzerland, 2Chiba, Japan, 3La Jolla, USA, 4Le Kremlin-Bicetre, France)
Successful factor VIII re-exposure after long-term aPCC prophylaxis in two hemophilia A patients with inhibitorsC. Königs1, A. Siegemund2, D. Stichel1, A. Orlowski1, C. Heller1, J. Kahle1, D. Schwabe1, U. Scholz2 (1Frankfurt, Germany, 2Leipzig, Germany)
rVIII-SingleChain in hemophilia A patients: A population pharmacokinetic modelY. Zhang2, J. Roberts2, D. Bensen-Kennedy2, A. Veldman1, K. S. Ledger2, J. Sidhu3 (1Marburg, Germany, 2King of Prussia, United States, 3Parkville, Australia)
Comparison of data security of the electronic patient diary smart medication with manual documentation in a paper diaryA. Roesch1, R. Fischer2, W. Mondorf3, D. Schmoldt1 (1Dreieich, Germany, 2Giessen, Germany, 3Frankfurt am Main, Germany)
Development and evaluation of a novel FVIII domain-specific immunoassay for characterization of anti-FVIII antibodiesB. Pezeshkpoor, A.-C. Berkemeier, J. Müller, T. Albert, J. Oldenburg (Bonn, Germany)
Activation and inactivation of rVIII-SingleChainC. Horn, H. J. Metzner (Marburg, Germany)
Protein Z - Does its analyzation make any clinical sense?G. Kappert, M. Daoud, M. Siebert, H. Rott, S. Halimeh (Duisburg, Deutschland)
Platelet aggregation testing on a routine coagulation analyzerW. Miesbach, B. Zwinge, R. Toenges, L. Karmal, V. Makki, S. Müller, S. Gundermann (Frankfurt, Germany)
Unambiguous and sensitive measurement of active coagulation proteasesA. Weber, A. Engelmaier, G. Prodinger (Vienna, Austria)
Quantification of TAFI in human plasma by LC-MS/MSM. Rauh, S. Weiß, K. Heußner, M. Chada, J. Zierk, W. Rascher, H.-G. Topf (Erlangen, Germany)
Diagnostic challenges of von Willebrand diseaseS. Schneppenheim, R. Dittmer, H. El-Abd Müller, U. Budde (Hamburg, Germany)
A rapid and simple assay for the determination of ADAMTS-13 activityM. Griffiths, H. Vetr, N. B. Binder (Vienna, Austria)
Evaluation and clinical validation of a chromogenic FIX assay for reliable post infusion measurements of recombinant and next generation factor IX productsJ. Müller, J. Oldenburg, B. Pötzsch (Bonn, Germany)
TechnoZym® ADAMTS-13 activity assay for determination of inhibitory antibodies against ADAMTS-13L. Wagner, F. Nasufi, M. Kafka, N. B. Binder (Vienna, Austria)
Measuring direct oral anticoagulants in standardized fully automated thrombin generation on Ceveron® alphaL. Wagner1, E. Wimmer2, J. Seier2, N. B. Binder1, A. C. Haushofer2 (1Vienna, Austria, 2Wels, Austria)
Evaluation of DOAC Interferences on Technoclot® PT OwrenL. Rosenmayr, L. Wagner, N. B. Binder (Vienna, Austria)
Difficulties in diagnosing antiphospholipid syndrome in patients undergoing DOAC therapyT. Flieder1, M. Weiser1, T. Eller2, M. Dittrich3, K. von Bargen1, F. Knüttgen1, A. Hohbein1, J. Kuhn1, C. Knabbe1, I. Birschmann1 (1Bad Oeynhausen, Germany, 2Bad Salzufflen, Germany, 3Würzburg, Germany)
Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in the one-stage assayA. Veldman1, A. Feussner1, U. Kalina1, K. St. Ledger2 (1Marburg, Germany, 2King of Prussia, PA, USA)
Development, validation and application of a polysialylation-dependent FVIII activity assay to measure SHP656 (BAX 0826), a next generation extended half-life recombinant factor VIII productA. Weber, S. Haindl, G. Mohr, A. Engelmaier (Vienna, Austria)
rVIII-SingleChain plasma activity can be measured using both the one-stage and the chromogenic substrate assay: Results from an international field studyA. Veldman1, A. Feussner1, U. Kalina1, H. Metzner1, C. Horn1, A. Stowers1, K. St. Ledger2 (1Marburg, Germany, 2King of Prussia, PA, United States)
Platelet-dependent von Willebrand factor activity - an important constituent of the diagnostic repository to classify von Willebrand syndrome.O. Tiebel, K. Trautmann, U. Platzbecker, R. Knöfler, G. Siegert (Dresden, Germany)
Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: comparison of diagnostic accuracy, reproducibility, and costs in clinical practiceA. Bankova1, Y. Andres2, M. Horn3, L. Alberio4, M. Nagler3 (1Lucerne, Switzerland, 2Muri, Switzerland, 3Bern, Switzerland, 4Lausanne, Switzerland)
Is platelet aggregation testing dependent on fibrinogen level?L. Graf, J. Worden, W. Korte (1St. Gallen, Switzerland)
Replacing the aPTT for monitoring of unfractionated heparin with the Prothrombinase induced Clotting Time (PiCT) significant influence on dosing.W. Korte, L. Graf, C. Knöpfel (1St. Gallen, Switzerland)
Clauss fibrinogen assay obviously underestimates fibrinogen level not confirmed in thromboelastometry A case reportT. Lang1, M. Rieke1, M. Bachler2, B. Schenk2, M. Hermann2, M. Tollnick1, D. Fries2 (1Hohne, Germany, 2Innsbruck, Austria)
A Flow cytometer-based platelet aggregation assay permits platelet function testing in small blood volumesS. Liedtke, J. Wesche, K. Althaus, T. Thiele, A. Greinacher (Greifswald, Germany)
Genetic heterogeneity in patients with von Willebrand disease type I: a regional study from Northeast GermanyM. Steiner, D. Jenzen, R. Toenges, D. Friday, B. Krammer-Steiner (Rostock, Germany)
Comparison of factor VIII assays using physiological triggersG. J. Praefcke, M. Kusch, C. Grundmann, S. Keitel, A. Hunfeld, R. Seitz (Langen, Germany)
The German Pediatric Hemophilia Research Database (GEPHARD) a project of the `Standing Committee Pediatrics of the Society for Thrombosis and Hemostasis Research´ to improve the quality of hemophilia care for childrenC. Bidlingmaier1, C. Escuriola Ettingshausen2, K. Kentouche3, M. Olivieri1, W. Eberl4, B. Zieger5, K. Kurnik1, C. Königs6, for the GEPHARD Study Group (1Munich, Germany, 2Mörfelden, Germany, 3Jena, Germany, 4Braunschweig, Germany, 5Freiburg, Germany, 6Frankfurt Main, Germany)
Acquired von Willebrand disease in infants with aortopulmonary shuntG. Wiegand1, V. Icheva1, U. Budde2, M. Hofbeck1 (1Tuebingen, Germany, 2Hamburg, Germany)
Late onset of thrombosis in siblings with homozygous protein C deficiencyC. Wermes, M. Suslovych, C. Detering, M. von Depka (Hannover, Germany)
Adolescent male suffering from thrombosis is not uncommonI. Wieland1, A. Biering2, K. W. Sykora1 (1Hannover, Germany, 2Wolfsburg, Germany)
Thrombotic events in the neonatal period a case series of common manifestationsM. Rohde, V. Vaillant, H. Ehrhardt, K.-P. Zimmer, B. Kemkes-Matthes, C. Mauz-Körholz, H. Hauch (Giessen, Germany)
Anterior spinal artery syndrome in pediatric patients: diagnostic and therapyA. M. Cseh, J. Kirschner, H. Meinicke, H. Fuchs, B. Zieger (Freiburg, Germany)
Systemic mast cell activation disease during adolescence and heparin levels in blood plasmaM. Vysniauskaite*, A. Selbitz, S. Unkrig, F.-J. Dumoulin, J. Homann, J. Oldenburg, G. J. Molderings*, H.-J. Hertfelder*, *equally contributing authors (Bonn, Germany)
Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca2+ signalingS. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (1Tübingen, Germany)
The special role of anti-ADAMTS13-IgA in acquired TTP: Production induced by infectious microorganisms?J. Falk, T. Vigh, I. Scharrer (Mainz, Germany)
Variable linkage with platelet functions of genetic mutations in ORAI1, STIM1 or FERMT3 in patients with severe immune deficienciesM. Nagy1, T. G. Mastenbroek1, N. J. A. Mattheij1, S. de Witt1, K. J. Clemetson2, J. Kirschner3, A. S. Schulz4, J. M. E. M. Cosemans1, B. Zieger3, J. W. M. Heemskerk1 (1Maastricht, The Netherlands, 2Bern, Switzerland, 3Freiburg, Germany, 4Ulm, Germany)
Phosphorylation of the protein phosphatase 2A inhibitor alpha-endosulfine (ENSA) at two distinct sites, serine 67 and serine 109, in human plateletsE. Walter1, O. Pagel2, R. Zahedi2, A. Smolenski3, S. Gambaryan1,4, U. Walter1, K. Jurk1 (1Mainz, Germany, 2Dortmund, Germany, 3Dublin, Ireland, 4St. Petersburg, Russia)
Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies in a cohort of 47 patients with acquired thrombotic thrombocytopenic purpuraG. Sinkovits, M. Réti, Z. Prohászka (Budapest, Hungary)
Intra- and intercellular fate of iron oxide nanoparticles in plateletsK. Aurich, J. Wesche, R. Koch, J. Fuhrmann, A. Greinacher (Greifswald, Germany)
Frequency and analysis of hospital cases of heparin induced thrombocytopenia type 2 (HIT 2) in GermanyS. Wahler1, A. Müller2 (1Hamburg, Germany, 2München, Germany)
Phenotyping platelets from patients with inherited platelet disorders by immunofluorescence microscopyK. Althaus1, C. Blumentritt1, U. Strobel1, T. Bakchoul2, A. Greinacher1 (1Greifswald, Germany, 2Tübingen, Germany)
Initiation of a prospective observational cohort study of patients with acquired thrombotic thrombocytopenic purpura (TTP)T. Falter1, A. Trinchero1, K. Jurk1, H. Roßmann1, K. Lackner1, B. Lämmle1,2, C. von Auer1 (1Mainz, Germany, 2Bern, Switzerland)
Evaluation of platelet parameters in pediatric thrombocytopenic patientsR. Knöfler, S. Hackel, B. Arneth, J. Lohse, J. Stächele, O. Tiebel (Dresden, Germany)
The power of large platelets: Comprehensive functionalcharacterizationoflarge and small platelets fromhealthy volunteers.S. Handtke, R. Palankar, M. Ferrara, S. Cauhan, A. Greinacher, T. Thiele (Greifswald, Germany)
Evaluation of platelet activation after electric cardioversionJ. Gaugler, A. Schlagenhauf, B. Egner, W. Schwinger, E. Bisping, S. Gallistl, H. Haidl (Graz, Austria)
Platelet dense granule production and dense granule release defects in pediatric patients with storage pool disorderJ. Eilenberger1, G. Manukjan1, O. Andres1, C. Schambeck2, S. Eber2, H. Schulze1 (1Würzburg, Germany, 2Munich, Germany)
Practical limitations of diagnostic algorithms in heparin induced thrombocytopenia: A case report.S. Nowak-Harnau, S. Enkel, B. Zimmermann, C. Reiss, T. Bakchoul (Tuebingen, Germany)
Supra-normal closure time caused by recombinant von Willebrand factor in PFAT. Kragh, M. Spannagl (Munich, Germany)
Prophylactic plasma treatment in patients with hereditary thrombotic thrombocytopenic purpuraZ. Cermakova1, P. Kovarova1, J. A. Kremer Hovinga2 (1Ostrava, Czech Republic, 2Bern, Switzerland)
Molecular genetic investigations and demonstration of founder effect in Osler-Rendu-Weber diseaseR. Gindele1, T. Major2, Z. Szabo1, K. B. Kovács1, G. Pfliegler1, Z. Bereczky1 (1Debrecen, Hungary, 2Eger, Hungary)
CLIC1 supports mechanisms related to thrombosis and vascular repairL. M. Knowles, P. Niewald, E. Ampofo, A. Drawz, I. Müller, H. Eichler, J. Pilch (Homburg, Germany)
Collagen V alpha 2 as a direct target of miR-143 in arteriogenesisT. Hammerschick1, K. Troidl2, K. T. Preissner1, S. Fischer1 (1Giessen, Germany, 2Bad Nauheim, Germany)
Activated protein C protects against accelerated atherosclerosis in diabetes by restricting p66shc expression in macrophagesK. Shahzad1, I. Gadi1, S. Nazir1, M. Al-Dabet1, S. Kohli1, S. Ranjan1, F. Bock1,2, B. Isermann1 (1Magdeburg, Germany, 2Nashville, United States)
Autophagy status in factor VIII secreting endothelial cellsM. A. Jamil, H. Singer, N. Nüsgen, J. Oldenburg, O. El-Maarri (Bonn, Germany)
Analysis of proteolytic von Willebrand factor (VWF) fragments in patients with VWF-related diseasesJ. Irle1, K. Schwierczek1, H. Rossmann1, T. Falter1, C. von Auer1, A. Trinchero1, K. Lackner1, Z. Ruggeri2, B. Lämmle1, K. Jurk1 (1Mainz, Germany, 2La Jolla, CA, USA)
In patients with uncontrolled arterial hypertension platelets and coagulation factor XI are responsible of modifications of thrombin generation.J. Lagrange, Y. Weihert, S. Kossmann, T. Münzel, S. Karbach, P. Wenzel (Mainz, Germany)
Investigating the interconnection between complement and coagulation in xenotransplantationR. Sfriso1, N. Klymiuk2, E. Wolf2, J. Seebach3, R. Rieben1 (1Bern, Switzerland, 2Munich, Germany, 3Geneva, Switzerland)
Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertensionS. Kossmann1, J. Lagrange1, S. Jackel1, K. Jurk1, M. Ehlken1, A. Daiber1, U. Walter1, T. Renné2,3, W. Ruf1,4, T. Munzel1, P. Wenzel1 (1Mainz, Germany, 2Hamburg, Germany, 3Stickholm, Schweden, 4La Jolla, USA)
Clinical relevance of marginal low Protein SP. Lodemann1, D. Peetz1, T. Held1, W. Ludwig1, J. Oldenburg2 (1Berlin, Germany, 2Bonn, Germany)
Characterisation of previously unknown protein C gene variantsS. Körber1, L. Böff1, F. Bergmann2, A. Czwalinna2, B. Bomke3, C. Heller1, M. Krause4, B. Luxembourg1, K. Kurnik5, W. Miesbach1, C. Geisen1 (1Frankfurt am Main, Germany, 2Hannover, Germany, 3Düsseldorf, Germany, 4Wiesbaden, Germany, 5Munich, Germany)
GE-CAT - German Evaluation of Cancer associated Thrombosis A prospective register trial for patients with hematological and oncological diseases and venous thromboembolism in BerlinA. Jühling, M. Sinn, E. T. Wolter, S. Bischoff, U. Pelzer, L. Wislocka, J. K. Striefler, F. Brandes, H. Riess, R. Klamroth (Berlin, Germany)
Study of fibrinolytic parameters in Indian patients with venous thrombosisA. Prabhudesai1, S. Shetty1, K. Ghosh2, B. Kulkarni1 (1Mumbai, India, 2Surat, India)
Characterization of antithrombin variants in thrombotic patients with normal and reduced activity.R. Deshpande1, B. Kulkarni1, K. Ghosh2, S. Shetty1 (1Mumbai, India, 2Surat, India)
Application of massive parallel sequencing searching for rare genetic variants associated with thrombophilia - implementation to clinical practice.P. Vrtel, L. Slavik, R. Vodicka, R. Vrtel, J. Ulehlova, J. Prochazkova, A. Hlusi, M. Palova, M. Prochazka (Olomouc, Czech Republic)
Advances in diagnosis, classification and management of lower extremity deep vein thrombosis (DVT), prevention of DVT recurrence and the post-thrombotic syndrome: personal experiences and appraisal of the literatureJ. J. Michiels1,2, W. Moossdorff1, J. M. Michiels1,3, M. U. Lao1, H. Maasland1, H. Smeets1, M. Han1, P. Dulicek4, V. Stvrtinova4,5, Z. Pecsvarady4, P. Poredos4,6, A. Gadisseur7, W. Schroyens7 (1Rijnmond Rotterdam, Netherlands, 2Rotterdam, Netherlands, 3Rotterdam-Zuid Rotterdam, Netherlands, 4Prague, Czech Republic, 5Bratislava, Slovakia, 6Ljubljana, Slovenia, 7Antwerp, Belgium)
The role of an endothelial specific g-protein coupled receptor in thrombosisL. Gottlob1, P. Dusart1, L. Fagerberg2, D. A. Trégouët3, P. Morange4, M. Germain3, M. Civelek5, T. Renne1,6, J. Odeberg1, L. Butler1 (1Stockholm, Sweden, 2Solna, Sweden, 3Paris, France, 4Marseille, France, 5Charlottesville, United States, 6Hamburg, Germany)
Angiogenesis in a porcine von Willebrand disease modelM. von Depka, H. Allerkamp, C. Pfarrer, M. Ekhlasi-Hundrieser, C. Detering, S. Lehner (Hannover, Germany)
Successful pregnancy in patient with homozygous sickle cell disease and prior pulmonary embolism a case reportJ. Notter, G. Amstad, B. Drexler, K. Loukidis (Basel, Switzerland)
Highly procoagulant extracellular vesicles in amniotic fluidJ. Thaler1, L. Hell1, L. Wisgrill1, C. Ay1, A. Spittler1, M. Schwameis1, B. Jilma1, P. Altevogt2, I. Pabinger1 (1Vienna, Austria, 2Heidelberg, Germany)
Dead fetus syndrome (DFS) in 2017 - a no more existing entity ? From individual patients to pathophysiological insightsF. Bergmann1, A. Czwalinna2, H. Groening1, R. Schwerdfeger1, R. Schild1, U. Budde2 (1Hannover, Germany, 2Hamburg, Germany)
Risk of pregnancy-associated recurrent venous thromboembolism (VTE) in women with a history of first venous thrombosisA. Gerhardt1,2, R. E. Scharf2, R. B. Zotz2 (1Ulm, Germany, 2Duesseldorf, Germany)
Comparison of two laboratory methods for thrombin generation in pregnancy with high risk for thrombosisM. Schwethelm, M. Martinez, I. Hoesli, D. Tsakiris (Basel, Switzerland)
Bernard Soulier syndrome in pregnancy and delivery a case reportK. Liebscher1, I. Niemann2, I. Bogner2, A. Siegemund3, M. Krause2, U. Scholz2 (1Leipzig, Germany, 2Leipzig, DE, 3Leipzog, DE)
Successful pregnancy outcome in a case of JAK2 positive essential thrombocytemia after treatment with peginterferon alpha-2bM.-V. Teleanu1, S. Jaramillo 1, S. Schönsteiner2, S. Estenfelder3, P. Schwarzwälder2, C. Langer2, M. Kull1 (1Ulm, Germany , 2Ulm, Germany, 3Ulm , Germany)
P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in miceJ. Merz, P. Stachon, P. Albrecht, F. Ünal, S. von Garlen, A. Heidenreich, N. Hoppe, B. Duffner, C. Bode, A. Zirlik (Freiburg, Deutschland)
Development and application of methods for the selective measurement of the human single amino acid exchange variant factor IX PaduaA. Weber1, A. Engelmaier1, D. Voelkel2, R. Pachlinger2, F. Scheiflinger1, H. Rottensteiner1 (1Vienna, Austria, 2Orth, Austria)
Fucoidans inhibit cellular responses to the chemokine IL-8 and the anaphylatoxin C5a better than heparinS. Alban, K. Ehrig, I. Liewert (Kiel, Germany)
The effect of storage on the platelet hemostatic activityE. V. Roitman, I. M. Kolesnikova (Moscow, Russia)
Evaluation of platelet hemostatic capacity using new thromboelastography-based assayE. V. Roitman, I. M. Kolesnikova (Moscow, Russia)
Blood rheology factors for thrombus formation in some oncohematological diseasesE. V. Roitman, I. M. Kolesnikova (Moscow, Russia)
Identification of novel mutations in FGA fibrinogen gene in Pakistani congenital afibrinogenemia patientsT. Khan1, A. Naz1, A. Biswas2, N. Ahmed3, S. Ahmed1, T. Shamsi1, J. Oldenburg2 (1Karachi, Pakistan, 2Bonn, Germany, 3Lahore, Pakistan)
Quantification of the antimetastatic effects of heparins by Single-cell force spectroscopyH. Schillers, A. Schmidt, S. Bobe, N. Martins-Castanheira (1Münster, Germany)
Gene polymorphism of plasminogen activator inhibitor-1 is a risk factor of thrombosis in patients with antiphospholipid syndromeL. Mukhametova, R. Aisina, T. Reshetnyak, L. Patrushev, K. Gershkovich (Moscow, Russia)
Combinations of recombinant staphylokinase (STA) and single-chain urokinase-type plasminogen activator (scuPA) induce synergistic thrombolysis in vitroR. Aisina, L. Mukhametova, K. Gershkovich, S. Varfolomeyev (Moscow, Russia)
Positive and negative role of oxidative stress in the prognosis of patients with gastric cancer.M. Kedzierska, J. Kolodziejczyk-Czepas, J. Jakubik, J. Piekarski, A. Jeziorski, P. Nowak, P. Potemski (Lodz, Poland)